Improvement of HBsAg Gene-Modified Dendritic Cell-Based Vaccine Efficacy by Optimizing Immunization Method or the Application of β-glucosylceramide

REFERENCES

• Beckebaum, S., Cicinnati, V. R., Zhang, X., Ferencik, S., Frilling, A., Grosse-Wilde, H., Broelsch, C. E., Gerken, G. (2003). Hepatitis B virus-induced defect of monocyte-derived dendritic cells leads to impaired T helper type 1 response in vitro: mechanisms for viral immune escape. Immunology 109: 487–495.
   PubMedGoogle Scholar
• Butterfield, L. H., Ribas, A., Potter, D. M., Economou, J. S. (2007). Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocelluar cancer. Cancer Immunol. Immunother. 56: 1931–1943.
   PubMed Web of Science ®Google Scholar
• Curti, A., Tosi, P., Comoli, P., Terragna, C., Ferri, E., Cellini, C., Massaia, M., D’Addio, A., Giudice, V., Di Bello, C., Cavo, M., Conte, R., Gugliotta, G., Baccarani, M., Lemoli, R. M. (2007). Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumor idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. Br. J. Haematol. 139: 415–424.
   PubMed Web of Science ®Google Scholar
• Draube, A., Klein-González, N., Mattheus, S., Brillant, C., Hellmich, M., Engert, A., von Bergwelt-Baildon, M. (2011). Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PloS One 6: e18801.
   PubMed Web of Science ®Google Scholar
• Evdokimova, V. N., Butterfield, L. H. (2008). Alpha-fetoprotein and other tumour-associated antigens for immunotherapy of hepatocellular cancer. Expert Opin. Biol. Ther. 8: 325–336.
   PubMed Web of Science ®Google Scholar
• Gao, J. D., Shao, Y. F., Xu, Y., Ming, L. H., Wu, Z. Y., Liu, G. T., Wang, X. H., Gao, W. H., Sun, Y. T., Feng, X. L., Liang, L. M., Zhang, Y. H., Sun, Z. T. (2005). Tight association of hepatocellular carcinoma with HBV infection in North China. Hepatobiliary Pancreat. Dis. Int. 4: 46–49.
   PubMedGoogle Scholar
• Hobbs, J. A., Cho, S., Roberts, T. J., Sriram, V., Zhang, J., Xu, M., Brutkiewicz, R. R. (2001). Selective loss of natural killer T cells by apoptosis following infection with lymphocytic choriomeningitis virus. J. Virol. 75: 10746–10754.
   PubMedGoogle Scholar
• Huang, C. H., Ou-Yang, L., Ma, H. H., Tang, Z. H., Li, G., Yao, J. L. (2003). Construction of replication-deficient recombinant adenoviral vector carrying HBV S and C region gene by homologous recombination in bacteria and its expression in vitro. World Chin. J. Digestol. 11: 438–441.
   Google Scholar
• Huck, S. P., Tang, S. C., Andrew, K. A., Yang, J., Harper, J. L., Ronchese, F. (2008). Activation and route of administration both determine the ability of bone marrow-derived dendritic cells to accumulate in secondary lymphoid organs and prime CD8 + T cells against tumors. Cancer Immunol. Immunother. 57: 63–71.
   PubMed Web of Science ®Google Scholar
• Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S., Steinman, R. M. (1992). Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony stimulating factor. J. Exp. Med. 176: 1693–1702.
   PubMed Web of Science ®Google Scholar
• Inafuku, M., Li, C., Kanda, Y., Kawamura, T., Takeda, K., Oku, H., Watanabe, H. (2012). Beta-glucosylceramide administration (i.p.) activates natural killer T cells in vivo and prevents tumor metastasis in mice. Lipids 47: 581–591.
   PubMedGoogle Scholar
• Lalazar, G., Preston, S., Zigmond, E., Ben Yáacov, A., Ilan, Y. (2006). Glycolipids as immune modulatory tools. Mini Rev. Med. Chem. 6: 1249–1253.
   PubMed Web of Science ®Google Scholar
• Liu, J., Fan, D. (2007). Hepatitis B in China. Lancet 369: 1582–1583.
   PubMed Web of Science ®Google Scholar
• Liu, Q., Zhai, B., Yang, W., Yu, L. X., Dong, W., He, Y. Q., Chen, L., Tang, L., Lin,Y., Huang, D. D., Wu, H. P., Wu, M. C., Yan, H. X., Wang, H. Y. (2009). Abrogation of local cancer recurrence after radiofrequency ablation by dendritic cell-based hyperthermic tumor vaccine. Mol. Ther. 17: 2049–2057.
   PubMed Web of Science ®Google Scholar
• Mizrahi, M., Lalazar, G., Ben Ya’acov, A., Livovsky, D. M., Horowitz, Y., Zolotarov, L., Adler, R., Shouval, D., Ilan, Y. (2008). Beta-glycoglycosphingolipid-induced augmentation of the anti-HBV immune response is associated with altered CD8 and NKT lymphocyte distribution: a novel adjuvant for HBV vaccination. Vaccine 26: 2589–2595.
   PubMedGoogle Scholar
• Ogasawara, K., Naruse, H., Itoh, Y., Gotohda, T., Arikawa, J., Kida, H., Good, R. A., Onoé,K. (1992). A strategy for making synthetic peptide vaccines. Proc. Natl. Acad. Sci USA 89: 8995–8999.
   PubMed Web of Science ®Google Scholar
• Ormandy, L.A., Farber, A., Cantz, T., Petrykowska, S., Wedemeyer, H., Horning, M., Lehner, F., Manns, M.P., Korangy, F., Greten, T. F. (2006). Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma. World J. Gastroenterol. 12: 3275–3282.
   PubMed Web of Science ®Google Scholar
• Qiu, S. J., Lu, L., Qiao, C., Wang, L., Wang, Z., Xiao, X., Qian, S., Fung, J. J., Ye, S. L., Bonham, C. A. (2005). Induction of tumor immunity and cytotoxic t lymphocyte responses using dendritic cells transduced by adenoviral vectors encoding HBsAg: comparison to protein immunization. J. Cancer Res. Clin. Oncol. 131: 429–438.
   PubMedGoogle Scholar
• Ribas, A. (2005). Genetically modified dendritic cells for cancer immunotherapy. Curr. Gene Ther. 5: 619–628.
   PubMed Web of Science ®Google Scholar
• Schmidt, T., Ziske, C., Märten, A., Endres, S., Tiemann, K., Schmitz, V., Gorschlüter, M., Schneider, C., Sauerbruch, T., Schmidt-Wolf, I. G. (2003). Intratumoral immunization with tumor RNA-pulsed dendritic cells confers antitumor immunity in a C57BL/6 pancreatic murine tumor model. Cancer Res. 63: 8962–8967.
   PubMed Web of Science ®Google Scholar
• Shi, M., Qian, S., Chen, W. W., Zhang, H., Zhang, B., Tang, Z. R., Zhang, Z., Wang,F. S.(2007). Hepatitis B virus (HBV) antigen-pulsed monocyte-derived dendritic cells from HBV-associated hepatocellular carcinoma patients significantly enhance specific T cell responses in vitro. Clin. Exp. Immunol. 147: 277–286.
   PubMedGoogle Scholar
• Shibolet, O., Alper, R., Zlotogarov, L., Thalenfeld, B., Engelhardt, D., Rabbani, E., Ilan, Y. (2003). NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells. Int. J. Cancer 106: 236–243.
   PubMedGoogle Scholar
• Shurin, M. R., Gregory, M., Morris, J. C., Malyguine, A. M. (2010). Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow? Expert Opin. Biol. Ther. 10: 1539–1553.
   PubMed Web of Science ®Google Scholar
• Stanic, A. K., De Silva, A. D., Park, J. J., Sriram, V., Ichikawa, S., Hirabyashi, Y., Hayakawa, K., Van Kaer, L., Brutkiewicz, R. R., Joyce, S. (2003). Defective presentation of the CD1d1-restricted natural Va14Ja18 NKT lymphocyte antigen caused by beta-D-glucosylceramide synthase deficiency. Proc. Natl. Acad. Sci. USA 100: 1849– 1854.
   PubMedGoogle Scholar
• Stoll, S., Delon, J., Brotz, T. M., Germain, R. N. (2002). Dynamic imaging of T cell-dendritic cell interactions in lymph nodes. Science 296: 1873–1876.
   PubMed Web of Science ®Google Scholar
• Wang, S., Hong, S., Wezeman, M., Qian, J., Yang, J., Yi, Q. (2007). Dendritic cell vaccine but not idiotype-KLH protein vaccine primes therapeutic tumor-specific immunity against multiple myeloma. Front Biosci. 12: 3566–3575.
   PubMedGoogle Scholar
• Whiteside, T. L., Piazza, P., Reiter, A., Stanson, J., Connolly, N. C., Rinaldo, C. R. Jr., Riddler, S. A. (2009). Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection. Clin. Vaccine Immunol. 16: 233–240.
   PubMedGoogle Scholar
• Xia, D., Zheng, S., Zhang, W., He, L., Wang, Q., Pan, J., Zhang, L., Wang, J., Cao, X. (2003). Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen. J. Mol. Med. (Berl). 81: 585– 596.
   PubMedGoogle Scholar
• Yang, J. Y., Cao, D. Y., Xue, Y., Yu, Z. C., Liu, W. C. (2010). Improvement of dendritic-based vaccine efficacy against hepatitis B virus-related hepatocellular carcinoma by two tumor-associated antigen gene-infected dendritic cells. Hum. Immunol. 71: 255– 262.
   PubMedGoogle Scholar
• Zhang, Y., Jiang, W., Fan, Y., Wen, J., Hao, W., Qian, M. (2008). Engirneering enhancement of the immune response to HBV DNA vaccine in mice by the use of LIGHT gene adjuvant. J. Virol. Meth. 153: 142–148.
   PubMedGoogle Scholar
• Zigmond, E., Preston, S., Pappo, O., Lalazar, G., Margalit, M., Shalev, Z., Zolotarov, L., Friedman, D., Alper, R., Ilan, Y. (2007). Beta-glucosylceramide: a novel method for enhancement of natural killer T lymphocyte plasticity in murine models of immune-mediated disorders. Gut 56: 82–89.
   PubMed Web of Science ®Google Scholar